AC Immune (STU:IMR) Construction In Progress : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is AC Immune Construction In Progress?

AC Immune's quarterly construction in progress declined from Sep. 2023 (€0.01 Mil) to Dec. 2023 (€0.00 Mil) but then stayed the same from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€0.00 Mil).

AC Immune's annual construction in progress declined from Dec. 2021 (€0.67 Mil) to Dec. 2022 (€0.00 Mil) and declined from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

AC Immune Construction In Progress Historical Data

The historical data trend for AC Immune's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Construction In Progress Chart

AC Immune Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

0.67

AC Immune Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															-	-	0.01	-	-

AC Immune Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

AC Immune (STU:IMR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (STU:IMR) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

ACIU:USA

Address

EPFL Innovation Park, Building B, Lausanne, CHE, 1015

Website

https://www.acimmune.com

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.

AC Immune (STU:IMR) Headlines

No Headlines